BROADWOOD PARTNERS, L.P. 4

What Happened
Broadwood Partners, L.P. (reported as a 10% owner) purchased 521,739 shares of Insight Molecular Diagnostics, Inc. (IMDX) common stock on February 10, 2026. The shares were acquired in a registered direct offering at $5.75 per share for a total purchase price of $2,999,999. This transaction is coded "P" for purchase.

Key Details

• Transaction date: 2026-02-10; filing date (Form 4): 2026-02-12 — filed timely (within the SEC’s two-business-day window).
• Price and size: 521,739 shares at $5.75 each = $2,999,999 total.
• Shares owned after the transaction: not specified in the filing.
• Important footnotes:
  • F1: Shares are directly owned by Broadwood Partners; may be deemed beneficially owned by Broadwood Capital, Inc. (general partner) and Neal C. Bradsher (president of Broadwood Capital). Each disclaims beneficial ownership except to the extent of pecuniary interest.
  • F3: Purchase was made under a Securities Purchase Agreement as a registered direct offering.
  • F4: Filing notes certain warrants are currently exercisable (not part of this reported common-share purchase).

Context
This is an institutional purchase by a reported 10% owner rather than an individual executive. Purchases by large shareholders can be seen as an investment vote of confidence, but the filing itself is purely factual and does not state motivation.